Dying with a Left Ventricular Assist Device as Destination Therapy

Shannon M Dunlay, Jacob J. Strand, Sara E. Wordingham, John M. Stulak, Angela J. Luckhardt, Keith M. Swetz

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background - Despite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. Methods and Results - All patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure (21%). Nearly half (46%) of the patients saw palliative care within 1 month before death; however, only 13 (15%) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78%) died in the hospital, of which 88% died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours. Conclusions - In contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care.

Original languageEnglish (US)
JournalCirculation: Heart Failure
Volume9
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Heart-Assist Devices
Terminal Care
Therapeutics
Hospices
Heart Failure
Electronic Health Records
Palliative Care
Documentation
Intensive Care Units
Cause of Death
Stroke

Keywords

  • end-of-life care
  • heart failure
  • left ventricular assist device
  • morbidity/mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Dying with a Left Ventricular Assist Device as Destination Therapy. / Dunlay, Shannon M; Strand, Jacob J.; Wordingham, Sara E.; Stulak, John M.; Luckhardt, Angela J.; Swetz, Keith M.

In: Circulation: Heart Failure, Vol. 9, No. 10, 01.10.2016.

Research output: Contribution to journalArticle

Dunlay, Shannon M ; Strand, Jacob J. ; Wordingham, Sara E. ; Stulak, John M. ; Luckhardt, Angela J. ; Swetz, Keith M. / Dying with a Left Ventricular Assist Device as Destination Therapy. In: Circulation: Heart Failure. 2016 ; Vol. 9, No. 10.
@article{c9ce7cc3777b40a5998402abf85e19c7,
title = "Dying with a Left Ventricular Assist Device as Destination Therapy",
abstract = "Background - Despite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. Methods and Results - All patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26{\%}), hemorrhagic stroke (24{\%}), and progressive heart failure (21{\%}). Nearly half (46{\%}) of the patients saw palliative care within 1 month before death; however, only 13 (15{\%}) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78{\%}) died in the hospital, of which 88{\%} died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours. Conclusions - In contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care.",
keywords = "end-of-life care, heart failure, left ventricular assist device, morbidity/mortality",
author = "Dunlay, {Shannon M} and Strand, {Jacob J.} and Wordingham, {Sara E.} and Stulak, {John M.} and Luckhardt, {Angela J.} and Swetz, {Keith M.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1161/CIRCHEARTFAILURE.116.003096",
language = "English (US)",
volume = "9",
journal = "Circulation: Heart Failure",
issn = "1941-3297",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Dying with a Left Ventricular Assist Device as Destination Therapy

AU - Dunlay, Shannon M

AU - Strand, Jacob J.

AU - Wordingham, Sara E.

AU - Stulak, John M.

AU - Luckhardt, Angela J.

AU - Swetz, Keith M.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Background - Despite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. Methods and Results - All patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure (21%). Nearly half (46%) of the patients saw palliative care within 1 month before death; however, only 13 (15%) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78%) died in the hospital, of which 88% died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours. Conclusions - In contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care.

AB - Background - Despite the ability of left ventricular assist device as destination therapy (DT-LVAD) to prolong survival for many patients with advanced heart failure, little is known about the eventual end-of-life care that patients with DT-LVAD receive. Methods and Results - All patients undergoing DT-LVAD at the Mayo Clinic in Rochester, Minnesota, from January 1, 2007, to September 30, 2014, who subsequently died before July 1, 2015, were included. Information about end-of-life care was obtained from documentation in the electronic medical record. Of 89 patients who died with a DT-LVAD, the median (25th-75th percentile) time from left ventricular assist device implantation to death was 14 (4-31) months. The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and progressive heart failure (21%). Nearly half (46%) of the patients saw palliative care within 1 month before death; however, only 13 (15%) patients enrolled in hospice a median 11 (range 1-315) days before death. Most patients (78%) died in the hospital, of which 88% died in the intensive care unit. In total, 49 patients had their left ventricular assist device deactivated before death, with all but 3 undergoing deactivation in the hospital. Most patients died within an hour of left ventricular assist device deactivation and all within 26 hours. Conclusions - In contrast to the general heart failure population, most patients with DT-LVAD die in the hospital and few use hospice. Further work is needed to understand these differences and to determine whether patients with DT-LVAD are receiving optimal end-of-life care.

KW - end-of-life care

KW - heart failure

KW - left ventricular assist device

KW - morbidity/mortality

UR - http://www.scopus.com/inward/record.url?scp=84992055568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992055568&partnerID=8YFLogxK

U2 - 10.1161/CIRCHEARTFAILURE.116.003096

DO - 10.1161/CIRCHEARTFAILURE.116.003096

M3 - Article

C2 - 27758809

AN - SCOPUS:84992055568

VL - 9

JO - Circulation: Heart Failure

JF - Circulation: Heart Failure

SN - 1941-3297

IS - 10

ER -